8. Post-surgical follow-up for non-small cell lung carcinoma: should we change our practice?

2015 ◽  
Vol 41 (11) ◽  
pp. S263-S264 ◽  
Author(s):  
Fahad Fahad ◽  
Mohammed Haris ◽  
Imran Hussain ◽  
Shilajit Ghosh
1997 ◽  
Vol 12 (4) ◽  
pp. 148-153 ◽  
Author(s):  
V. Gendreau ◽  
F. Montravers ◽  
C. Philippe ◽  
J.N. Talbot

The prescription of bone scans (BS) in the initial staging and follow-up of small cell lung carcinoma (SCLC) is a traditional attitude. The availability of the serum neuron-specific enolase (NSE) assay and budget limitations led us to evaluate retrospectively, in 57 patients, the consequences of a more selective attitude, namely to perform BS only in those patients with abnormal serum NSE levels. Both BS and NSE assays were performed in 47 patients referred for initial staging of SCLC; NSE levels were normal in 8 but in 2 of these cases (25%) secondary bone localizations with great clinical significance were discovered at BS. During follow-up, 59 BS were performed in conjunction with NSE assays; 45 NSE levels were in the normal range whereas 17 (38%) corresponding BS were suggestive of bone metastases. In conclusion, due to the frequent occurrence of false-negative results in patients with bone metastases, serum NSE levels proved to be useless in the selection for BS of patients suffering from SCLC.


2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document